A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity in the liver
14040047
Phase 1 other active
Quick answer
A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity in the liver for No targeted indication. Male and female subjects with obesity. is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- No targeted indication. Male and female subjects with obesity.
- Phase
- Phase 1
- Modality
- other
- Status
- active